# US 2003/0073656 A1 · Methods for the treatment of hepatic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073656 A1
- Document ID: US20030073656A1
- Status: Published application
- Kind: A1
- Application number: 10/123,036
- Filed: 2002-04-15
- Published: 2003-04-17
- Earliest claimed: 2001-04-13
- Assignees: Children's Hospital Medical Center
- Inventors: Susan E. Waltz; Mike A. Leonis; Sandra J. Degen
- Web page: https://patentgrep.com/patent/US20030073656A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the prevention and treatment of injury and diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system. Specifically, the present invention relates to methods for decreasing the action of the RON receptor tyrosine kinase in liver physiology. More specifically, the present invention relates to the use of analogs and antagonists and antibodies for inhibiting the action of the RON receptor tyrosine kinase for the prevention and treatment of liver injury or damage in acute and chronic clinical conditions.

## Claims

### Claim 1

A method for the treatment of hepatobiliary damage in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a RON receptor tyrosine kinase inhibitor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the RON receptor inhibitor is selected from the group consisting of Ron receptor nucleic acid inhibitors, HGFL nucleic acid inhibitors, HGFL protein analogs, HGFL protein antagonists, HGFL blocking antibodies, RON receptor blocking antibodies, and fragments and derivatives thereof, in a suitable pharmaceutical composition.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the RON receptor tyrosine kinase inhibitor is an antibody capable of binding the RON receptor and preventing activation of the RON receptor by HGFL.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is an HGFL protein analog capable of binding the RON receptor without activating the RON receptor tyrosine kinase.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is an HGFL protein antagonist capable of binding the RON receptor without activating the RON receptor tyrosine kinase.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the HGFL protein antagonist is a polypeptide comprising an amino acid sequence at least 6 amino acids in length that includes at least 4 contiguous amino acids of a polypeptide sequence shown in SEQ ID NO: 2.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is an RON receptor antagonist capable inhibiting the activity of the RON receptor in causing liver damage or death of hepatocytes.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the RON receptor antagonist is a polypeptide comprising an amino acid sequence at least 6 amino acids in length that includes at least 4 contiguous amino acids of a polypeptide sequence shown in SEQ ID NO: 4.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the RON receptor antagonist interferes with the binding of ligand.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the RON receptor antagonist interferes with the receptor dimerization with another protein receptor tyrosine kinase.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is a nucleic acid inhibitor.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the nucleic acid inhibitor is an antisense molecule.

### Claim 13 (depends on 2)

The method according to claim 2, wherein the composition further comprises at least one additional therapeutic agent.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the composition further comprises at least one additional component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, emulsifiers, solubilizers, and stabilizers.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the at least one additional therapeutic agent is selected from the group consisting of chemotherapeutics, amino acids, antisense molecules, vitamins, immunoadjuvants, growth factors, proteins with growth factor-like activities, such as cytokines or cytokine antagonists, tissue plasminogen activator, antioxidants, nitric oxide donors and compounds capable of inducing nitric oxide generation or other therapeutics.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the at least one additional therapeutic agent is an antioxidant selected from the group consisting of an agent such as methionine, choline, N-acetylcysteine, vitamins, gluthathione, cysteine, and 2-mercaptoethanol.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the at least one additional therapeutic agent is an inhibitor of phosphatidylinositol 3-kinase.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the inhibitor of phosphatidylinositol 3-kinase is selected from the group consisting of wortmannin, LY294002 (Affiniti, Exeter, UK), viridin, viridiol, demethoxyviridin, demethoxyviridiol, and analogs and derivatives thereof.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the hepatobiliary system injury is acute liver failure.

### Claim 20 (depends on 2)

The method according to claim 2, wherein the hepatobiliary system injury is chronic liver failure.

### Claim 21 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is a pharmaceutically acceptable salt.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the RON receptor inhibitor is a prodrug.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the composition is administered orally, intravenously, transcutaneously or transdermally.

### Claim 24 (depends on 15)

The method according to claim 15, wherein the at least one additional therapeutic agent is a therapeutically effective amount of a nitric oxide stimulator.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the nitric oxide stimulator is one or more agents selected from the group consisting of nitric oxide donors, NO synthase (NOS) stimulators, and NO catabolism inhibitors.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the nitric oxide stimulator is a nitric oxide donor selected from the group consisting of nitroglycerin, amyl nitrate, nitroprusside, isosorbide dinitrate, erythityl dinitrate, and pentaerythritol tetranitrate.

### Claim 27 (depends on 2)

The method according to claim 2, wherein the RON receptor inhibitor is capable of binding to the RON receptor and thereby inhibits receptor homo or heterodimerization with another protein receptor tyrosine kinase.

### Claim 28

A method for preventing hepatobiliary damage in a subject due to exposure to a hepatotoxic agent, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a RON receptor tyrosine kinase inhibitor wherein the RON receptor inhibitor effectively ameliorates liver damage due to exposure to the hepatotoxic agent.

### Claim 29 (depends on 28)

The method of claim 28, wherein the hepatotoxic agent is a therapeutic agent selected from the group consisting of anesthetics, neuropsychotropics, anticonvulsants, analgesics, hormones, antimicrobials, cardiovascular drugs, immunosuppressives, radiation, and anitneoplastics.

### Claim 30 (depends on 29)

The method of claim 29, wherein the administering of RON receptor inhibitor is initiated within 24 hours after exposure.

### Claim 31

A pharmaceutical composition comprising a RON receptor inhibitor with at least one additional component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, emulsifiers, solubilizers, and stabilizers.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the inhibitor is derived from human HGFL.

### Claim 33 (depends on 32)

The composition of claim 32 wherein the inhibitor is a polypeptide comprising an amino acid sequence at least 80% identical to amino acids sequence of SEQ ID NO: 2.

### Claim 34 (depends on 32)

The composition of claim 32, wherein the inhibitor is a polypeptide comprising an amino acid sequence at least 95% identical to amino acids sequence of SEQ ID NO: 2.

### Claim 35 (depends on 31)

The composition of claim 31, wherein the inhibitor is a polypeptide comprising an amino acid sequence at least 6 amino acids in length that includes at least nine contiguous amino acids of a sequence coded for by on e or more of the mut ant HGFL oligonucleotide sequences selected from the group consisting of ΔPAP, ΔK1, ΔK2, ΔK, ΔK4, ΔK1K2, ΔL, K1K2, Glu, Xa, IIa, and 48G, and retains its abilities as a RON receptor inhibitor.

### Claim 36 (depends on 31)

The composition of claim 31, wherein the length of the polypeptide molecule consists of 10 to 100 amino acids.

### Claim 37 (depends on 31)

The composition of claim 31, wherein the RON receptor inhibitor is a HGFL truncated protein capable of binding a RON receptor with activation of secondary messengers by the RON receptor and wherein the length of protein molecule consists of 10 to 100 amino acids.

### Claim 38 (depends on 35)

The composition of claim 35, wherein the composition further comprises at least one additional therapeutic agent.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the composition further comprises at least one additional component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, emulsifiers, solubilizers, and stabilizers.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the at least one additional therapeutic agent is selected from the group consisting of chemotherapeutics, amino acids, vitamins, immunoadjuvants, growth factors, proteins with growth factor-like activities, such as cytokines or cytokine antagonists, phosphatidylinositol 3-kinase inhibitors, tissue plasminogen activators, antioxidants, nitric oxide donors and compounds capable of inducing nitric oxide generation or other therapeutics.

### Claim 41 (depends on 39)

The composition of claim 39, wherein the at least one additional therapeutic agent is an antioxidant selected from the group consisting of an agent such as methionine, choline, N-acetylcysteine, vitamins, gluthathione, cysteine, and 2-mercaptoethanol.

### Claim 42 (depends on 39)

The composition of claim 39, wherein the at least one additional therapeutic agent is at least one inhibitor of phosphatidylinositol 3-kinase selected from the group consisting of wortmannin, LY294002, viridin, viridiol, demethoxyviridin, demethoxyviridiol, and analogs and derivatives thereof.

### Claim 43 (depends on 39)

The composition of claim 39, wherein the RON receptor inhibitor is a pharmaceutically acceptable salt.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the RON receptor inhibitor is a prodrug.

### Claim 45 (depends on 43)

The composition of claim 43, wherein the at least one additional therapeutic agent is at least one nitric oxide stimulator selected from the group consisting of nitric oxide donors, NO synthase (NOS) stimulators, and NO catabolism inhibitors.

### Claim 46 (depends on 43)

The method according to claim 43, wherein the nitric oxide stimulator is a nitric oxide donor selected from the group consisting of nitroglycerin, amyl nitrate, nitroprusside, isosorbide dinitrate, erythityl dinitrate, and pentaerythritol tetranitrate.
